CW Advisors LLC Grows Holdings in Kenvue Inc. $KVUE

Key Points

• CW Advisors LLC increased its holdings in Kenvue Inc. by 24.4%, owning 142,940 shares worth approximately $3.42 million as of the latest SEC filing.
• Kenvue reported $0.29 earnings per share (EPS) for the last quarter, surpassing analysts' expectations, but experienced a 4% decline in revenue year-over-year.
• The company recently announced a quarterly dividend increase to $0.2075 per share, reflecting a 3.8% yield and marking a rise from the previous dividend of $0.21.

CW Advisors LLC lifted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 24.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,940 shares of the company's stock after buying an additional 27,991 shares during the quarter. CW Advisors LLC's holdings in Kenvue were worth $3,424,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Candriam S.C.A. grew its position in shares of Kenvue by 19.9% in the 1st quarter. Candriam S.C.A. now owns 135,052 shares of the company's stock worth $3,239,000 after buying an additional 22,425 shares during the period. GM Advisory Group LLC grew its position in shares of Kenvue by 7.1% in the 1st quarter. GM Advisory Group LLC now owns 160,819 shares of the company's stock worth $3,856,000 after buying an additional 10,616 shares during the period. Humankind Investments LLC grew its position in shares of Kenvue by 4.0% in the 1st quarter. Humankind Investments LLC now owns 27,220 shares of the company's stock worth $653,000 after buying an additional 1,049 shares during the period. Credit Agricole S A grew its position in shares of Kenvue by 34.8% in the 1st quarter. Credit Agricole S A now owns 694,016 shares of the company's stock worth $16,643,000 after buying an additional 179,120 shares during the period. Finally, Banco Bilbao Vizcaya Argentaria S.A. boosted its stake in Kenvue by 1.0% in the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 171,692 shares of the company's stock worth $4,123,000 after purchasing an additional 1,755 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

KVUE opened at $21.5950 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The stock has a market capitalization of $41.44 billion, a P/E ratio of 29.18, a P/E/G ratio of 3.10 and a beta of 0.83. The company's 50-day simple moving average is $21.52 and its two-hundred day simple moving average is $22.43. Kenvue Inc. has a 52-week low of $19.75 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to analysts' expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business's revenue for the quarter was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th will be paid a dividend of $0.2075 per share. The ex-dividend date is Wednesday, August 13th. This represents a $0.83 annualized dividend and a yield of 3.8%. This is an increase from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio (DPR) is currently 112.16%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on KVUE shares. Citigroup dropped their price target on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. UBS Group dropped their price target on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. JPMorgan Chase & Co. dropped their price target on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Barclays dropped their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Tuesday, July 15th. Finally, Canaccord Genuity Group dropped their price target on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.